It was billed as a debate on sky-high prescription drug prices — but once again, middlemen known as pharmacy benefit managers took center stage.

A panel of policy experts and biotech veterans who gathered at Harvard on Tuesday focused much of their ire on the role of insurance. Though they disagreed on plenty — like who is ultimately responsible for high drug prices — all concluded that people would probably be better off if the health care system killed copays, which some argue gives patients “skin in the game” that can keep them from using health services or drugs they don’t need.

Unlock this article by subscribing to STAT Plus and enjoy your first 30 days free!


What is it?

STAT Plus is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.

What's included?

  • Daily reporting and analysis
  • The most comprehensive industry coverage from a powerhouse team of reporters
  • Subscriber-only newsletters
  • Daily newsletters to brief you on the most important industry news of the day
  • Online intelligence briefings
  • Frequent opportunities to engage with veteran beat reporters and industry experts
  • Exclusive industry events
  • Premium access to subscriber-only networking events around the country
  • The best reporters in the industry
  • The most trusted and well-connected newsroom in the health care industry
  • And much more
  • Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.
  • This has to be the stupidest idea I ever heard !!!!! The PBM’s are hoping the government would do something as dumb as this !!! More for them to steal !!

Comments are closed.

A roundup of STAT’s top stories of the day in science and medicine

Privacy Policy